Electrophysiologic and antiarrhythmic actions of sulphinpyrazone and its sulfide metabolite G25671.
In anesthetized dogs, the cumulative intravenous administration of 1.0-40.0 mg/kg sulphinpyrazone failed to alter the ventricular excitation threshold, ventricular refractory period and ventricular fibrillation threshold determined during nonobstructed coronary blood flow. Sulphinpyrazone, however, did attenuate the reduction in the ventricular fibrillation threshold occurring during transient myocardial ischemia. G25671, the sulfide metabolite of sulphinpyrazone, failed to alter ventricular refractoriness and 'nonischemic' ventricular fibrillation thresholds, and was minimally effective in reducing the decrease in 'ischemic' fibrillation thresholds when administered in cumulative intravenous doses of 5.0-20.0 mg/kg. In conscious dogs in the subacute phase of anterior myocardial infarction, the administration of a cumulative 10.0-40.0 mg/kg sulphinpyrazone failed to alter the mode of induction, rate or morphology of ventricular tachyarrhythmias initiated by programmed ventricular stimulation. These data suggest that neither sulphinpyrazone nor its sulfide metabolite possess primary electrophysiologic properties which might contribute directly to significant antiarrhythmic or antifibrillatory activity.
D000818:Animals; D000889:Anti-Arrhythmia Agents; D003327:Coronary Disease / Q000503:physiopathology; D016861:Cyclooxygenase Inhibitors; D004285:Dogs; D004594:Electrophysiology; D008297:Male; D009203:Myocardial Infarction / Q000503:physiopathology; D013442:Sulfinpyrazone / Q000031:analogs & derivatives* / Q000494:pharmacology*; D014693:Ventricular Fibrillation / Q000503:physiopathology
D000889:Anti-Arrhythmia Agents; D016861:Cyclooxygenase Inhibitors; C042257:G 25671; D013442:Sulfinpyrazone